The stock of Catalent Inc (NYSE:CTLT) is a huge mover today! About 738,993 shares traded hands. Catalent Inc (NYSE:CTLT) has risen 3.73% since March 8, 2016 and is uptrending. It has underperformed by 5.59% the S&P500.
The move comes after 5 months negative chart setup for the $3.15 billion company. It was reported on Oct, 11 by Barchart.com. We have $23.55 PT which if reached, will make NYSE:CTLT worth $157.50M less.
Catalent Inc (NYSE:CTLT) Ratings Coverage
Out of 6 analysts covering Catalent (NYSE:CTLT), 3 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 50% are positive. Catalent has been the topic of 12 analyst reports since September 3, 2015 according to StockzIntelligence Inc. The rating was downgraded by Wells Fargo to “Market Perform” on Tuesday, December 22. The firm has “Mkt Perform” rating given on Wednesday, December 9 by Raymond James. The stock has “Hold” rating given by Jefferies on Thursday, September 10. The rating was maintained by Deutsche Bank with “Hold” on Wednesday, November 4. Wells Fargo upgraded the shares of CTLT in a report on Tuesday, June 21 to “Outperform” rating. As per Thursday, September 3, the company rating was maintained by Bank of America. The stock of Catalent Inc (NYSE:CTLT) earned “Hold” rating by Jefferies on Thursday, September 29. Bank of America upgraded the shares of CTLT in a report on Monday, June 20 to “Buy” rating. Morgan Stanley downgraded the stock to “Ewu” rating in Thursday, April 21 report.
According to Zacks Investment Research, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey.”
Insitutional Activity: The institutional sentiment increased to 1.74 in Q2 2016. Its up 0.77, from 0.97 in 2016Q1. The ratio improved, as 23 funds sold all Catalent Inc shares owned while 38 reduced positions. 26 funds bought stakes while 80 increased positions. They now own 124.13 million shares or 1.11% less from 125.52 million shares in 2016Q1.
Voya Mngmt Lc last reported 41,688 shares in the company. State Street reported 3.60M shares or 0.01% of all its holdings. Teachers Retirement Sys Of The State Of Kentucky last reported 0.14% of its portfolio in the stock. Teacher Retirement System Of Texas holds 0% of its portfolio in Catalent Inc (NYSE:CTLT) for 14,158 shares. Envestnet Asset Management Incorporated last reported 0% of its portfolio in the stock. Proshare Advsrs Ltd Liability Co accumulated 24,614 shares or 0.01% of the stock. Kornitzer Management Ks reported 199,310 shares or 0.08% of all its holdings. Walleye Trading Lc reported 4,243 shares or 0% of all its holdings. Blackstone Group Inc Ltd Partnership, a New York-based fund reported 17.10 million shares. Bank & Trust Of America Corp De last reported 801,856 shares in the company. Zurcher Kantonalbank (Zurich Cantonalbank) owns 2,935 shares or 0% of their US portfolio. Amalgamated Bank & Trust holds 12,040 shares or 0.02% of its portfolio. Princeton Alpha Mngmt L P last reported 0.06% of its portfolio in the stock. Moreover, Teachers has 0.01% invested in Catalent Inc (NYSE:CTLT) for 158,725 shares. Hsbc Public Limited Company has 0% invested in the company for 16,401 shares.
Insider Transactions: Since May 27, 2016, the stock had 0 insider purchases, and 3 sales for $619.18 million net activity. On Friday, May 27 the insider WALSH MATTHEW M sold $611,533. Shares for $403.23M were sold by Blackstone Management Associates V L.L.C..
CTLT Company Profile
Catalent, Inc., incorporated on March 14, 2007, is a well-known provider of delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. The Company’s divisions include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels, including traditional softgel capsules (in which the shell is made from animal-derived materials), and Vegicaps and OptiShell capsules (in which the shell is made from vegetable-derived materials). The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products using its OptiMelt, OptiPact, OptiForm and Zydis technologies, other drug delivery technologies, such as prefilled syringes; blow-fill seal unit dose manufacturing, including its ADVASEPT technology; biologic cell line development, including its GPEx and SMARTag technologies; and analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for customer required patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.